You have recently been diagnosed with breast or ovarian cancer and it has been suggested that you consider genetic testing. Why? Why now? How will this help? What will I or my doctor do with the results? This short video will help address these key questions and better prepare you for a visit with a cancer genetic counselor who can fully address all of your concerns. We want to empower you to make an informed decision about your health for you and your family.
Просмотров: 335 Allina Health
In this video, Dr. Jyoti Patel explains how genetic testing works to improve personalized medicine, the role that family history and certain mutations play in cancer, and understanding the genetics of your disease.
Просмотров: 6717 Cancer.Net
Kurtis Davies, PhD, with the University of Colorado Health Sciences Center Department of Pharmacology, joined GRACE for our Webinar Series on Molecular Diagnostic Testing and Next Generation sequencing in Lung Cancer. In this video, Dr. Davies explains genetic testing in lung cancer. Please visit our forums at http://cancergrace.org/forum/q-and-a-..., and scroll to the bottom of the page to ask a question! http://cancerGRACE.org/
Просмотров: 92 GRACE - Global Resource for Advancing Cancer Education
It could be your mom, sister, aunt or best friend. One out of 8 women will get breast cancer in her lifetime. A small subset of the women who get diagnosed have inherited an abnormal copy of a gene that runs in families and can greatly increase their risk of certain cancers. One question these women and their families face is, "Should I get tested to find out if I have a genetic risk?" The answer is always a very personal one.
Просмотров: 17307 Mayo Clinic
This breast cancer lecture explains about the brca gene (brca1 and brca2 mechanism) mutation which leads to the development of breast cancer. A BRCA mutation is a mutation in both of the genes BRCA1 and BRCA2. Detrimental mutations in these tumor suppressor genes produce a hereditary breast-ovarian melanoma syndrome in affected families. Mutations in BRCA1 and BRCA2 are distinctive, and breast cancer is relatively original, so these mutations consequently account for only five to ten percent of all breast cancer cases in women. 1000s of distinctive types of mutations in these genes have been recognized. Excessive-danger mutations, which disable an primary error-free DNA repair procedure (homology directed repair), tremendously develop the character's threat of setting up breast cancer, ovarian melanoma and specific different cancers. Why BRCA1 and BRCA2 mutations lead preferentially to cancers of the breast and ovary is not identified, but lack of BRCA1 function seems to result in non-useful x-chromosome inactivation. No longer all mutations are excessive-chance; some show up to be harmless editions. The cancer hazard related to any given mutation varies greatly and depends on the distinctive variety and area of the mutation and in all probability different person reasons. Ladies with unsafe mutations in either BRCA1 or BRCA2 have risk of breast melanoma that is about five occasions the average chance, and a hazard of ovarian cancer that's about ten to thirty occasions common. BRCA1 mutations typically confer a higher danger of breast and ovarian melanoma in females than BRCA2 mutations. Having a high-threat mutation does no longer guarantee that the girl will increase any sort of cancer, or warranty that any melanoma that appears was once genuinely induced through the mutation, alternatively than every other element, like alcohol consumption. For more information, log on to- http://www.shomusbiology.com/ Get Shomu's Biology DVD set here- http://www.shomusbiology.com/dvd-store/ Download the study materials here- http://shomusbiology.com/bio-materials.html Remember Shomu’s Biology is created to spread the knowledge of life science and biology by sharing all this free biology lectures video and animation presented by Suman Bhattacharjee in YouTube. All these tutorials are brought to you for free. Please subscribe to our channel so that we can grow together. You can check for any of the following services from Shomu’s Biology- Buy Shomu’s Biology lecture DVD set- www.shomusbiology.com/dvd-store Shomu’s Biology assignment services – www.shomusbiology.com/assignment -help Join Online coaching for CSIR NET exam – www.shomusbiology.com/net-coaching We are social. Find us on different sites here- Our Website – www.shomusbiology.com Facebook page- https://www.facebook.com/ShomusBiology/ Twitter - https://twitter.com/shomusbiology SlideShare- www.slideshare.net/shomusbiology Google plus- https://plus.google.com/113648584982732129198 LinkedIn - https://www.linkedin.com/in/suman-bhattacharjee-2a051661 Youtube- https://www.youtube.com/user/TheFunsuman Thank you for watching
Просмотров: 21200 Shomu's Biology
Dr. Deborah Lindner weighs in Watch Uma Pemmaraju talk about Breast Cancer and Cancer on Americas News Hq.
Просмотров: 1431 Fox News
An animation explaining the genetic basis of cancer... oncogenes, tumor suppressors, BRCA gene testing, and cancer gene sequencing. Narrated by Sean Connery (not really). by D.R. double B (Brett Baskovich) Narrated by Mario Silva and Rick Cerveza
Просмотров: 12148 DRdoubleB
Building on our rich history of innovation, genome scientists, bioinformaticians and molecular pathologists at Memorial Sloan Kettering Cancer Center have developed a targeted tumor sequencing test, MSK-IMPACT™ (Integrated Mutation Profiling of Actionable Cancer Targets), to detect gene mutations and other critical genetic aberrations in both rare and common cancers. The ultimate goal of the MSK-IMPACT™ test is to use clinical molecular laboratory testing to improve oncologists’ ability to treat people with solid cancers by giving them a better understanding of the genetic underpinnings of each patient’s illness.
Просмотров: 4023 Memorial Sloan Kettering
Researchers have developed a new way to diagnose cancer with greater accuracy before tumors are detected using imaging by instead testing for tumor cell DNA in the blood. Patients with very early stages of cancer have DNA from tumor cells circulating in their blood long before an actual tumor develops, researchers say, which may allow for earlier treatment of the disease. Tumor cell molecules can be discovered in a regular blood sample before a tumor is visible via imaging such as tomography, X-ray, ultrasound or MRI. http://www.upi.com/Health_News/2017/05/22/Scientists-develop-flexible-DNA-barcoding-test-to-detect-cancer/3401495464161/ http://www.wochit.com This video was produced by YT Wochit News using http://wochit.com
Просмотров: 91 Wochit News
Keynote: Solving Molecular Analysis of Cancer: From DNA to Proteins - Sam Greenblatt, CTO, Nano Global This session will focus on the networking requirements using open source to treat diseases through cell-based analysis at the molecular level. Transporting this knowledge across devices and centers requires a whole new structure and networking. Terabits per second with high-availability and guaranteed delivery is required to meet the needs. Shared knowledge is the critical for real-time analysis. This will discuss data flows, open networking, and databases that are all open source and have been optimized for this problem. About Sam Greenblatt Sam is authoring a book on Human Assisted Deep Learning. Sam is a consultant to technology companies to define strategies and offers technology services beyond the company's business strategy. He will focus on the strategic requirements of clients' businesses by working with them to determine long-term technology-related decisions and create the appropriate operating model. Mr. Greenblatt is a Technologist in Residence at several technology companies. He uses his background as a technologist and his history of successfully helping companies bring technology to market. Helping the management team of these companies source and evaluate potential technology, particularly in areas where he applies his background. Sam served as CTO and General Manager of Engineering Solutions at Dell providing solutions, to have strong alliances, develop cross-line of business offerings. He offered a cohesive architecture that made customers’ offerings run better with the workloads that meet these needs. He is a recognized expert in Object Technology, IaaS, PaaS, and HPC (Red Hat OpenStack, Azure, HyperV, VMware). He built solutions based on Cloud, Analytics, Big Data, and Enterprise Applications (SAP and Oracle). He was the chief architect, in and technologist at the Enterprise Solution Group involved in the architecture, communication and technical promotion of Dell's Enterprise family of products. Sam has served on USDL (Linux Foundation) 4 years, Object Management Group (11 years), Eclipse Board (1 Year), and the DMTF Board 2 Years. He is the primary inventor on 4 US Patents in Object Technology. He was a CTO at Hewlett-Packard, Candle Corporation and Chief Innovation Officer at Computer Associates. Sam also was an adjunct professor of Computer Science at both Temple University and LaSalle University.
Просмотров: 820 The Linux Foundation
In this informative webchat, Duke Cancer Institute’s gynecologic oncology expert Angeles Secord, MD and patient advocate Katya Lezin discuss the rapidly changing field of genetic testing in ovarian cancer. Dr. Secord discusses what genetic testing can mean for you and your family and answers your questions on genetic testing. Following Dr. Secord’s discussion and Q&A session, Katya Lezin, patient advocate and ovarian cancer survivor, shares her experience as a BRCA positive ovarian cancer survivor.
Просмотров: 195 OMNIConnect
Welcome to the Library of You. An animated short film, featuring Gene, the Genomic librarian, introducing the genetics of a problem that affects millions of us - cancer. Gene shows us how Genetic Testing and Genetic Counseling can help you, your family and your healthcare providers make informed decisions. Animation produced by Worker Studio in Centennial, Colorado (worker-studio.com) http://www.worker-studio.com/animated-promotional-video-528904.html Produced in a cutting-edge animation pipeline blending high-end 3D and 2D animation, motion graphics, 2.5D multiplane cameras, and the latest 2D performance capture techniques from Adobe, this project signifies an exciting new direction for Worker Studio. DIRECTOR/LEAD ANIMATOR: Michael "Ffish" Hemschoot PRODUCER/WRITER/SCORE: Jason Cangialosi STORYBOARDS/ILLUSTRATOR/2D ANIMATOR: Katrina Sass CHARACTER DESIGNER/ILLUSTRATOR: Scott Brooks 3D ANIMATOR: Anastasia Todd MOTION GRAPHIC DESIGNER: Feni Hagman MOTION GRAPHIC ANIMATOR: Bryce Kaufman 3D CHARACTER MODELER/RIGGER: Brandon Perlow
Просмотров: 301 Worker Studio Animation
Download from iTunes: https://itunes.apple.com/us/podcast/cancer-early-detection-genetic/id431848216?i=279543665. Breast cancer, ovarian cancer and colon cancer are the most common cancer types that are tested for inherited mutations. Banu Arun, M.D., professor of Breast Medical Oncology; Karen Lu, M.D., professor and chair of Gynecologic Oncology and Reproductive Medicine; and Nancy You, M.D., assistant professor of Surgical Oncology; all part of MD Anderson Cancer Center's Clinical Cancer Genetics Program, discuss the role of genetics in cancer.
Просмотров: 1314 MD Anderson Cancer Center
The team in the Sol Goldman Pancreatic Cancer Research Center at Johns Hopkins has developed and is currently testing a bold new approach for the early detection of cancer. The approach is based on the detection of small amounts of DNA released by small cancers into the blood stream. It is our hope that this approach will allow clinicians to detect small curable cancers. This test is currently under development and is not available clinically at this time.
Просмотров: 3076 Johns Hopkins Pathology
Ignyta’s molecular diagnostic testing allows us to move beyond a “one-size-fits-all” approach to cancer treatment. Visit http://ignyta.com to learn more. Ignyta is leading the way in advancing targeted therapies to the patients who need them the most. Our Dx efforts aim to pair our precision therapeutic candidates with biomarker-based companion diagnostics that rapidly identify the patients most likely to benefit from the therapies we develop. With the launch of Ignyta’s Trailblaze Pharos™ diagnostic suite, we are now able to identify actionable gene fusions in solid tumors that may qualify for enrollment in the STARTRK-2 cancer clinical trial. Ignyta’s Trailblaze™ diagnostic programs leverage both Immunohistochemistry (IHC) screening and Next-Generation Sequencing (NGS) to identify tumors that may respond to entrectinib, just one of Ignyta’s targeted therapies in development. Learn more about the importance of molecular testing if you’ve been diagnosed with cancer at Ignyta.com. And for more information on NTRK, ROS1, and ALK molecular diagnostic testing for enrollment in the STARTRK-2 cancer clinical trial, visit http://www.STARTRKtrials.com.
Просмотров: 237 Ignyta, Inc
Color Genomics has come up with a saliva kit that tests for two types of gene mutations linked to breast cancer and ovarian cancer. While traditional tests can cost $4,000, this kit only costs $249. But will it be effective? CBS News chief medical correspondent Dr. Jon LaPook reports.
Просмотров: 18528 CBS Evening News
The field of molecular genetics of cardiovascular disease has made great strides in our understanding of the etiologies, cellular biology, and mechanisms responsible for heart disease in recent years. In addition, stem cell therapy and other novel genetic-based treatments are on the horizon. These updates will be provided.
Просмотров: 1016 AAPexperience
http://cancerGRACE.org/ Dr. Jack West reviews new techniques for evaluating mutations from blood, including detection of circulating tumor cells (CTCs) or mutations in circulating free DNA (cfDNA) that can replace at least some tissue biopsies.
Просмотров: 1333 GRACE - Global Resource for Advancing Cancer Education
What if humans could be edited to run faster, jump higher, and think bigger? What if disease could be eradicated before it ever came to be? These are the questions that no longer belong in just comic books, but in the laboratory of the Innovative Genomics Institute’s Scientific Director, Jacob Corn. In this talk, he explores the future and ethics of CRISPR/Cas-9 genome editing. [AV and event video provided by http://repertoireproductions.com]. Jacob Corn is the Managing Director and Scientific Director of the Innovative Genomics Initiative and faculty at UC Berkeley in the department of Molecular & Cell Biology. Jacob’s research generally bridges reductionist mechanism with cell biology, with the overarching goal of understanding how biophysical properties interact within the cellular environment to shape signaling behavior and how disease arises when these properties go awry. As the director of the IGI, Jacob is committed to pushing the boundaries of next-generation genome editing for transformative insights into fundamental biologies and to laying the groundwork for clinical and commercial applications of the technology. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx
Просмотров: 48367 TEDx Talks
Bradley J. Monk, MD, FACS, FACOG; Kathleen Moore, MD; Leslie M. Randall, MD, MAS; Oliver Dorigo, MD, PhD; and Thomas Herzog, MD, review recommendations for counseling and testing patients for germline and somatic BRCA mutations as well as consider the role of cell-free tumor DNA testing in ovarian cancer.
Просмотров: 43 OncLiveTV
Genomic sequencing technologies have enabled increasing use of cancer genetic testing for both inherited cancer predisposition and somatic mutation profiling in tumors. This presentation reviews interplay between germline and somatic findings in cancer genetic testing, with particular emphasis on new areas of clinical utility. These new areas include germline testing of cancer predisposition genes to guide cancer treatment decisions, tumor DNA sequencing to rule out Lynch syndrome, and tumor DNA sequencing used to inform germline variant classification. Colin C. Pritchard, MD, PhD Associate Professor Director of Clinical Diagnostics, Brotman Baty Institute for Precision Medicine Co-Director, Genetics and Solid Tumors Laboratory Head, Genetics Division Dept. of Laboratory Medicine University of Washington 10/17/18 http://depts.washington.edu/labweb/Education/ContEdu/ http://uwtv.org
Просмотров: 51 UW Video
Dr. Druley will discuss novel strategies for single molecule DNA and RNA sequencing as a modality for characterization of clonal hematopoiesis and minimal residual disease (MRD) detection in cancer. Despite "deep sequencing," next-generation platforms have an error rate of 0.5-1.0%, precluding straightforward sequencing for MRD, which requires sensitivity of less than 1:1,000. However, using a single molecule labeling strategy to correct sequencing errors, the Druley lab has published multiple studies identifying rare clonal mutations at levels as low as 1:10,000 from heterogenous DNA samples. His group is now moving this strategy into RNA sequencing to identify aberrant slice isoforms, allele-specific expression and cryptic fusions in addition to point mutations. The ultimate goal is to combine a toolbox of technologies for precise genomic characterization of individual cancers with machine learning to improve molecular diagnostics, risk stratification, therapeutic selection and outcomes for children with cancer. Dr. Druley is a board-certified pediatric hematologist/oncologist and Assistant Professor of Pediatrics, Developmental Biology and Genetics at Washington University School of Medicine. Research in the Druley Lab is based on characterizing the link between abnormal human development and early childhood cancer, particularly infant leukemia. The lab has a track record for genomic methodology development and is currently applying that technology to improve molecular diagnostics in pediatric AML. Clinically, Dr. Druley is focused on pediatric cancer predisposition and serves as the co-director of the Pediatric Cancer Predisposition Program at St. Louis Children’s Hospital.
Просмотров: 99 DE-CTR ACCEL
Predictive genetic tests for cancer risk genes nhs choices. Genetic testing for breast cancer and ovarian. Genetic testing for breast cancer and ovarian at the university of michigan comprehensive center people a high risk may have inherited an altered gene, such as brca1 or brca2 gene. Find out more about genetic testing for breast. Breast cancer bracelets help support survivorsbrca1 and brca2 risk genetic testing fact sheet for breast national brca1 & mutations what is who should get it or gene webmd. Do you need genetic testing for breast cancer? . 10 feb 2017 three of the most well known genes that can mutate and raise the risk of breast and or ovarian cancer are brca1, brca2, and palb2 what does a positive brca1 or brca2 genetic test result mean? Breast and ovarian cancers associated with brca1 and brca2 mutations tend to develop who should be tested for brca? While brca1 and brca2 gene mutations may increase your odds of developing breast cancer, your odds of having either genetic testing gives people the chance to learn if their family history of breast cancer is due to an inherited gene mutation. Breast cancer information newly diagnosed? . Most women who get breast cancer 27 sep 2012 so, really needs to be concerned about this and should consider genetic testing? Furthermore, if you do have a gene 22 jan 2017 webmd helps understanding what is involved in undergoing testing determine may at risk for assessing family history of ovarian with fra boc uses maximum eight involves first searching mutation basic overview it is, samples are needed the most common genes hereditary cancers 10 apr many types tests used today, more being known increase some other cancers) 1 2016 brca test blood that dna analysis identify harmful changes (mutations) either one two answers frequently asked questions link between we pioneers diagnostic. Contra el cncer saber informate, cuidate, apoyanos sales. Molecular testing for cancer greenwood genetic center ggc. Today, the 28 gene myriad myrisk hereditary cancer test is keeping us at 2 jun 2015 currently tests are available for faults that increase risk of breast cancer, bowel ovarian womb and prostate although genetic testing accessible becoming increasingly cheaper it not always helpful in clarifying many a fault genes brca1, brca2 or tp53 results high. This was the reason since your grandmother, mom or sister has had breast cancer, it's got you wondering do need genetic testing to find out if you're more likely develop hereditary inherited cancer can because of a gene mutation less common than most people think only 5 10. Genetic testing for breast cancer johns hopkins myriad genetics. Women at risk of having a faulty gene are offered testing, screening and the 5 may 2015 variant brca greatly increases woman's chance developing breast cancer ovarian. Patients & families genetic testing for cancer risk brca in australia breast genes live well nhs choices. Md anderson inherited risk breast cancer foundation nz. University of genetic testing breast cancer in families.
Просмотров: 10 Last Question
Recommended for Patients and Health Professionals Excerpts from AACC Annual Meeting Educational Event: Improving Patient Care with Molecular Testing: Current and Future Impacts. Presented by Catherine M. Behrens, MD, PhD, FACOG - Consultant, Roche Molecular Systems Helpful terms for video viewing: ASCUS - atypical squamous cells of undetermined significance; Colposcopy - a procedure in which a health practitioner uses a lighted magnifying instrument to examine a woman's cervix for abnormal areas, to take samples for biopsy, and/or treat as indicated To learn more, visit: https://labtestsonline.org/understanding/analytes/hpv/tab/test
Просмотров: 1645 LabTestsOnline
The capacity to detect new cancers, treatment-resistant variants, and tumor heterogeneity by noninvasive technology on the basis of tumor DNA in the blood promises to revolutionize cancer detection, prevention, and treatment. Application of Cell-free DNA Analysis to Cancer Treatment: https://nej.md/2yKlbhN
Просмотров: 908 NEJMvideo
DNA diagnosis has become easier with the availability of high throughput technologies. Molecular testing is available in many laboratories, and can be done for genetic disorders, some malignancies/cancers etc. A confirmation by DNA testing enables appropriate genetic conseling and prenatal diagnosis for some severe early onset disorders.In some cases a diagnosis may help in planning specific therapy or management or facilitate subsequent monitoring in the family. Several techniques are available like PCR based tests, FISH, MLPA, microarray and next generation sequencing etc.
Просмотров: 244 Inusha Panigrahi
Oncologist have long dreamed of avoiding the subjective nature of reported signs and the hit-or-miss nature of biopsies. Their dreams maybe coming true. Tests known as “liquid biopsies” uncover signs of actual DNA, or cell-free circulating tumor DNA (ctDNA), which is shed from a tumor into the bloodstream. The advantage is that ctDNA is more than 100 times more abundant in the blood than tumor cells. While studies are still underway, the market is adjusting to make way for this revolutionary cancer test. Annual sales are forecast to be $10 billion, and several companies are developing testing kits to hit the market this year. The frontier of the liquid biopsy is wide open. It’s being hailed as a flagship technology of the federal government’s Cancer Moonshot Initiative. Experts believe it’s only a matter of time before catching and treating cancer is as routine as your annual checkup.
Просмотров: 10904 Cleveland Clinic
Created by Ross Firestone. Watch the next lesson: https://www.khanacademy.org/test-prep/mcat/biomolecules/genetic-mutations/v/the-different-types-of-mutations?utm_source=YT&utm_medium=Desc&utm_campaign=mcat Missed the previous lesson? https://www.khanacademy.org/test-prep/mcat/biomolecules/gene-control/v/tumor-suppressors?utm_source=YT&utm_medium=Desc&utm_campaign=mcat MCAT on Khan Academy: Go ahead and practice some passage-based questions! About Khan Academy: Khan Academy offers practice exercises, instructional videos, and a personalized learning dashboard that empower learners to study at their own pace in and outside of the classroom. We tackle math, science, computer programming, history, art history, economics, and more. Our math missions guide learners from kindergarten to calculus using state-of-the-art, adaptive technology that identifies strengths and learning gaps. We've also partnered with institutions like NASA, The Museum of Modern Art, The California Academy of Sciences, and MIT to offer specialized content. For free. For everyone. Forever. #YouCanLearnAnything Subscribe to Khan Academy’s MCAT channel: https://www.youtube.com/channel/UCDkK5wqSuwDlJ3_nl3rgdiQ?sub_confirmation=1 Subscribe to Khan Academy: https://www.youtube.com/subscription_center?add_user=khanacademy
Просмотров: 130554 khanacademymedicine
Genetic testing for breast cancer is a simple blood test that can help determine a patient's likelihood of developing breast cancer. Genetic testing looks for the BRCA1 and BRCA2 breast cancer genes that have been found to be linked with the development of breast cancer. Dr. Harness gives us more details into this type of testing. Click Here To Get Dr. Harness' 15 Breast Cancer Questions To Ask Your Doctor http://www.breastcanceranswers.com/what-breast-cancer-questions-to-ask/# Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, http://www.breastcanceranswers.com/ask This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.
Просмотров: 9706 Breast Cancer Answers®
Are you looking to start using blood samples in your translational research? Maybe you’re interested in metastatic breast cancer, or non-small cell lung. Or maybe the challenges and limitations of solid tumor samples have you thinking… it’s time. Now what? Let’s take a closer look at DNA yield, and the reality of working with cell-free DNA from plasma. Cell-free DNA (or cfDNA) refers to all non-encapsulated DNA in the blood stream. A portion of that cell-free DNA originates from a tumor clone and is called circulating tumor DNA (or ctDNA). cfDNA are nucleic acid fragments that enter the bloodstream during apoptosis or necrosis. Normally, these fragments are cleaned up by macrophages, but we believe the overproduction of cells in cancer leaves more of the cfDNA behind. These fragments average around 170 bases in length, have a half-life of about two hours, and are present in both early and late stage disease in many common tumors including non-small cell lung and breast. That said, cfDNA concentration varies greatly, occurring at between 1 and 100,000 fragments per millilitres of plasma. If you’ve been in the NGS space for a while, you might want to know about sensitivity and specificity. We demonstrated high sensitivity and specificity for variants at frequency greater than point one percent with 20 nanograms input DNA, and greater than point five percent with 5 nanograms . To see more on how to do that, check out our video on cfDNA assays. You may have heard about using cfDNA for analyses at point zero one percent limit of detection. While the technology exists to reach .01% (digital droplet for example), there’s a biological limit we need to talk about. From a 10 mL blood sample, using the Applied Biosystems MagMAX Cell-Free DNA Isolation Kit, we routinely obtain about 20 nanograms of cfDNA, or around 6 usable molecules for analysis. Some quick math shows us that at 1% limit of detection, we can expect around 25 molecules. At 0.1% only 2-3 molecules are expected to be present. That means below 0.1% there may not be any molecules present for analysis. Remember, too, that cfDNA concentrations are highly variable. They can be very low at critical stages such as early recurrence or development of resistance, where many researchers are now focused. To successfully isolate 20 nanograms of DNA from blood plasma, both manual and automated methods are available depending on your throughput needs. DNA in hand, your research dictates which path to take at this point. You might choose digital PCR for recurrence monitoring studies. For research in therapy selection, a next-generation sequencing assay may be preferred. Wherever your liquid biopsy research takes you, we can help you get there with complete solutions for cfDNA analysis from just a few targets to multi-gene assays. I hope we’ve given you some things to think about as you consider using cell-free DNA in your lab. But I’m sure you’ll have some questions. So submit your questions at thermofisher.com/ask and subscribe to our channel to see more videos like this. And remember, when in doubt, just Seq It Out!
Просмотров: 8361 Thermo Fisher Scientific
Radiation is all around us and a part of everyday life. But what exactly is it and what does it do to our bodies? Watch the premiere of Life After: Chernobyl, Tuesday, April 26 at 10/9c on Animal Planet! Sign Up For The TestTube Newsletter Here ►►►► http://bit.ly/1myXbFG Read More: Non-Ionizing Radiation https://www.osha.gov/SLTC/radiation_nonionizing/ "Non-ionizing radiation is described as a series of energy waves composed of oscillating electric and magnetic fields traveling at the speed of light. Non-ionizing radiation includes the spectrum of ultraviolet (UV), visible light, infrared (IR), microwave (MW), radio frequency (RF), and extremely low frequency (ELF). Lasers commonly operate in the UV, visible, and IR frequencies." Radiation Therapy- National Cancer Institute http://www.cancer.gov/publications/patient-education/radiationttherapy.pdf "Radiation therapy (also called radiotherapy) is a cancer treatment that uses high doses of radiation to kill cancer cells and stop them from spreading. At low doses, radiation is used as an x-ray to see inside your body and take pictures, such as x-rays of your teeth or broken bones. Radiation used in cancer treatment works in much the same way, except that it is given at higher doses." How Does Nuclear Radiation Harm the Body? http://www.livescience.com/13250-radiation-health-effects-japan-nuclear-reactor-cancer.html "There's been some reported evidence that radioactive iodine and cesium are being released into the environment from the malfunctioning nuclear reactors in Japan, said Kathryn Higley, director of the Oregon State University department of nuclear engineering and radiation health physics." ____________________ DNews is dedicated to satisfying your curiosity and to bringing you mind-bending stories & perspectives you won't find anywhere else! New videos twice daily. Watch More DNews on TestTube http://testtube.com/dnews Subscribe now! http://www.youtube.com/subscription_center?add_user=dnewschannel DNews on Twitter http://twitter.com/dnews Trace Dominguez on Twitter https://twitter.com/tracedominguez Lissette Padilla on Twitter https://twitter.com/lizzette DNews on Facebook https://facebook.com/DiscoveryNews DNews on Google+ http://gplus.to/dnews Discovery News http://discoverynews.com Download the TestTube App: http://testu.be/1ndmmMq Sign Up For The TestTube Mailing List: http://dne.ws/1McUJdm
Просмотров: 504612 Seeker
Target Ovarian Cancer is proud to be funding Dr Marc Tischkowitz and his team to undertake the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) clinical study. Hear more about this vital study and how it seeks to assess whether it is acceptable, feasible and cost-effective for women to be offered genetic testing at the time of diagnosis without standard genetic counselling? Find out more about the study: http://www.targetovariancancer.org.uk/our-research/our-research-projects Find out more about our research: http://www.targetovariancancer.org.uk/our-research
Просмотров: 913 Target Ovarian Cancer
A 7-minute presentation about the truth about DNA Testing In Detection of Prostate Cancer. Visit http://dnamazing.com
Просмотров: 1274 yongjj
Daniel S. Oh, MD, assistant professor of surgery, University of Southern California, Keck School of Medicine, discusses myPlan genetic testing in patients with lung cancer. MyPlan is a molecular diagnostics test that uses the paraffin embedded surgical resection specimen, as well as representative slides, says Dr. Oh. A real-time PCR-based platform is then conducted, and it is run on gene-expression of some cell cycle progression genes. The scoring system is combined with the clinical stage, which produces the prognostic score, which is stratified into high-risk and low-risk. Typically, myPlan is used on stage I and stage II patients with lung cancer, adds Oh. It is particularly useful for stage Ib because there is a lot of controversy over who to treat with chemotherapy. Oh says it is also useful for stage II patients because they have a very wide distribution of risk; some with high-risk and some with low-risk.
Просмотров: 171 Targeted Oncology
Part of a weekly segment on Cancer and Genetics, CNN discusses previvors and genetic testing with Dr. Ora Karp Gordon, MD, MS. Dr. Gordon is Director of the GenRISK Adult Genetics Program and Genetics Director of the Wasserman Breast Cancer Risk Reduction Program. She also is a geneticist at the Saul and Joyce Brandman Breast Center and the Thyroid Cancer Center at Cedars-Sinai. She is an assistant clinical professor at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA).
Просмотров: 1748 Lisa Marton
Air date: Wednesday, February 22, 2012, 3:00:00 PM Time displayed is Eastern Time, Washington DC Local Category: Wednesday Afternoon Lectures Description: G. Burroughs Mider Lecture Established in 1968 in honor of the first NIH director of laboratories and clinics. The lecture is presented by an NIH intramural scientist to recognize and appreciate outstanding contributions to biomedical research. DNA mismatch repair and translesion synthesis are two essential processes accompanying (or associated with) DNA replication and cell division to ensure genome stability and integrity. Failure in either of these processes leads to an increased mutation rate in all organisms and increased cancer propensity in humans. Although the genes and proteins involved in these pathways were identified more than ten years ago, we are still far away from understanding the molecular mechanisms and from the ultimate goal of using our knowledge to conquer cancer. In this seminar, I will show what we have learned about these processes using structural and molecular approaches. The focus will be on (1) how the mismatch repair proteins MutS and MutL remove mutations and protect us from colon cancers and Lynch Syndrome, and (2) how the special human DNA polymerase functions as a double agent that reduces both UV-damage induced skin cancers and the efficacy of platinum-based chemotherapy. The NIH Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide. For more information, visit: The NIH Director's Wednesday Afternoon Lecture Series Author: Wei Yang, Ph.D., Section Chief, Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, NIH Runtime: 00:59:14 Permanent link: http://videocast.nih.gov/launch.asp?17125
Просмотров: 5319 nihvcast
A new gene test may help identify slow-growing prostate cancers that will require treatment, a new study suggests. The test revealed the levels of "expression" of three aging-related genes and could be used to predict whether seemingly slow-growing prostate cancer will remain slow-growing, according to Columbia University Medical Center researchers. Using the three-gene test along with existing cancer-staging tests could help doctors better determine which men with early prostate cancer can be safely monitored and spared the potential risks of prostate removal or other invasive treatments, the study authors suggested. The investigators assessed the test in 43 prostate cancer patients who had been monitored for at least 10 years. All of the men had initially been diagnosed with low-risk cancer, but 14 eventually developed advanced prostate cancer. All 14 of those patients were correctly identified by the three-gene test, according to the study, which was published online Sept. 11 in the journal Science Translational Medicine. The researchers plan to conduct a larger study to assess the test's accuracy. "Most of the 200,000 prostate cancers diagnosed each year in the U.S. are slow-growing and will remain so, but the three-gene biomarker could take much of the guesswork out of the diagnostic process and ensure that patients are neither overtreated nor undertreated," study leader Cory Abate-Shen, a professor of urological oncology at Columbia University Medical Center, said in a university news release. And, as study co-author Dr. Mitchell Benson, chairman and professor of urology at the medical center, explained in the news release: "The problem with existing tests is that we cannot identify the small percentage of slow-growing tumors that will eventually become aggressive and spread beyond the prostate." Currently, men diagnosed with low-risk prostate cancer can choose either active surveillance, which includes regular testing and monitoring but risks missing the window when the disease is localized and potentially curable, or aggressive treatment, which can cause serious side effects such as urinary incontinence and impotence. Dr. Louis Kavoussi is chairman of urology at North Shore-LIJ's Arthur Smith Institute for Urology in New Hyde Park, N.Y. He said: "Men getting a diagnosis of prostate cancer are initially shocked and begin conjuring images of themselves as desperate, dying patients. In reality, the majority of patients with prostate cancer do not die of the disease, and a large portion can be managed with observation. This study looks at novel molecular tools to help define which patients can be managed conservatively, and avoid potential side effects and expensive treatments." Dr. Aaron Katz, chairman of urology at Winthrop-University Hospital in Mineola, N.Y., said: "In the current era, it is clear that PSA screening has detected many men with prostate cancer. In the years past, we believed that all men needed to be treated. The good news is that many men who are found to have these abnormal cells in their prostate may not need any treatment. With advances in genomics and DNA testing, we are now able to stratify those men with indolent disease, and prevent unnecessary treatment."
Просмотров: 383 Heath and Beauty
(Visit: http://www.uctv.tv/) When a killer infection spreads in the movies, the doctors triage and isolate the patients while a medical biologist races to diagnose the illness and find a cure. Inevitably a national emergency follows as the virus or bacteria wipe out an unsuspecting population. While this may be Hollywood's vision, Reg Beer, the Medical Diagnostics Initiative Leader at Lawrence Livermore National Laboratory, explains the Lab-on-Chip technologies he develops for time-critical Molecular Diagnostics applications. Recorded on 01/26/2013. Series: "Field Trip at the Lab: Science on Saturday" [12/2013] [Science] [Show ID: 25750]
Просмотров: 3837 University of California Television (UCTV)
Kory Jasperson, Certified Genetic Counselor and Vice Chairperson, Hereditary Colon Cancer Foundation
Просмотров: 34 Hereditary Colon Cancer Foundation
The Profile research study is creating one of the largest databases of genetic abnormalities in cancer. More than 15,000 tumor samples have been genetically sequenced and the results are beginning to shed more light on just what makes certain cancers tick. In this video, scientists show how genetic testing in cancer happens -- from tumor sample collection to data analysis -- and talk about the promise that the technology holds for cancer research and care. More information about Profile — a collaboration between Dana-Farber Cancer Institute, Brigham and Women's Hospital and Boston Children's Hospital — is at Http://www.dana-farber.org/Profile. Transcription: Speaker 1: Just dropping off some specimens. Speaker 2: Thank you. Reporter: It’s here in the pathology lab where tumor samples are brought in for testing. The samples are from cancer patients who have consented to be part of the Profile Project, a large research study to help speed the development of personalized cancer care with precision treatments. Dr. William Hahn is the deputy chief scientific officer at Dana-Farber Cancer Institute. He helps lead the joint project with Brigham and Women’s Hospital and Boston Children’s Hospital. Dr. Hahn: We’re really excited about it, because it really represents our first foray into using molecular techniques to understand cancers, rather than anatomical criteria, and that means that all of the knowledge we’ve learned over the last 30 or 40 years about what makes cancers tick, we can now try to get at the basis of that within the DNA of a tumor. Reporter: To get the DNA, technologists isolate a sample from the tumor, and then it’s put on a slide to be checked by pathologists for quality. Dr. Neil Lindeman is the direct of the Center for Advanced Molecular Diagnostics at Brigham and Women’s Hospital where the tumor samples are then processed. Dr. Lindeman: What we’re trying to do is we’re trying to understand the genetic causes of cancers—what genes specifically are causing what cancer and how it behaves in each patient, one at at a time. And we’re using a very sophisticated and high-throughput technology that enables us to test for a lot of different changes—hundreds at once—in a lot of different patients. Reporter: That sophisticated technology allows scientists to scan tumor DNA for cancer-related abnormalities in more than 300 genes. Dr. Lindeman: This is the instrument that we use to fragment DNA… Reporter: One of the first steps in the process is breaking up the DNA into small fragments using a sonicator. Dr. Lindeman: To the principle of sonication is sound waves—ultrasound—setting up vibrations that sheer the DNA, and by tuning the sonicator to the right frequency, you can generate fragments that are roughly equal size. Reporter: Those DNA fragments are then placed into a sequencer, which uses light signals and a computer to read each letter of the DNA code and look for cancer-related changes. Dr. Hahn: What modern sequencers do is instead of doing this in a one-base-at-a-time linear manner, they sequence thousands or hundreds of thousands of pieces of DNA in a parallel manner, and then we reassemble all of that data to come up with the overall sequence. So, one way to think about this is instead of doing things one after another after another, we’re doing a million processes all at once and then taking that data and combining it at the end. Reporter: With the sequencing complete, the data are interpreted by a team of cancer investigators. The goal is to identify the specific cause of the patient’s cancer and then determine which treatment will be the most effective. Now that the project has logged more than 5,000 tumor profiles, researchers are starting to look for leads to new cancer discoveries. Dr. Lindeman: Well, I’d like to see this being done for everybody routinely continuing, and I’d like to see this transition from being a research project to a clinical project. I think results should be available in the medical record, and physicians taking care of patients should be able to see these results and act on them. Dr. Hahn: So, in the past, when we’ve looked at cancers using the best tools that we had, it was largely looking at a black box. We could discern the edges and feel a little bit about what it was that cancer might be, but we had know way of comprehensively interrogating exactly what makes up cancer. This is the first step to being able to take away that black box and really understand what it is that makes a cancer tick.
Просмотров: 1930 Dana-Farber Cancer Institute
For more information, log on to- http://shomusbiology.weebly.com/ Download the study materials here- http://shomusbiology.weebly.com/bio-materials.html A single-nucleotide polymorphism (SNP, pronounced snip; plural snips) is a DNA sequence variation occurring when a single nucleotide — A, T, C or G — in the genome (or other shared sequence) differs between members of a biological species or paired chromosomes in a human. For example, two sequenced DNA fragments from different individuals, AAGCCTA to AAGCTTA, contain a difference in a single nucleotide. In this case we say that there are two alleles. Almost all common SNPs have only two alleles. The genomic distribution of SNPs is not homogenous; SNPs usually occur in non-coding regions more frequently than in coding regions or, in general, where natural selection is acting and fixating the allele of the SNP that constitutes the most favorable genetic adaptation. Other factors, like genetic recombination and mutation rate, can also determine SNP density. SNP density can be predicted by the presence of microsatellites: AT microsatellites in particular are potent predictors of SNP density, with long (AT)(n) repeat tracts tending to be found in regions of significantly reduced SNP density and low GC content. Within a population, SNPs can be assigned a minor allele frequency — the lowest allele frequency at a locus that is observed in a particular population. This is simply the lesser of the two allele frequencies for single-nucleotide polymorphisms. There are variations between human populations, so a SNP allele that is common in one geographical or ethnic group may be much rarer in another. These genetic variations between individuals (particularly in non-coding parts of the genome) are exploited in DNA fingerprinting, which is used in forensic science . Also, these genetic variations underlie differences in our susceptibility to disease. The severity of illness and the way our body responds to treatments are also manifestations of genetic variations. For example, a single base mutation in the APOE (apolipoprotein E) gene is associated with a higher risk for Alzheimer disease. Source of the article published in description is Wikipedia. I am sharing their material. Copyright by original content developers. Link- http://en.wikipedia.org/wiki/Main_Page
Просмотров: 112433 Shomu's Biology